Article
Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations.
Current oncology (Toronto, Ont.) - 3 Nov 2021
Petiteau Constance, Robinet-Zimmermann Gwladys, Riot Adèle, Dorbeau Marine, Richard Nicolas, Blanc-Fournier Cécile, Bibeau Frédéric, Deshayes Simon, Bergot Emmanuel, Gervais Radj, Levallet Guénaëlle
Abstract excerpt
Epidermal growth factor receptor (EGFR) genotyping, a critical examen for the treatment decisions of patients with non-small cell lung cancer (NSCLC), is commonly assayed by next-generation sequencing (NGS), but this global approach takes time. To determine whether rapid EGFR genotyping tests by the IdyllaTM system guides earlier therapy decisions, EGFR mutations were assayed by both the IdyllaTM system and NGS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
